Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03042702 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer

A Phase 2 study of Ovarian Cancer, sponsored by Innovation Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
2
Enrollment target
2
Study locations

NCT03042702: Completed Phase 2 study of Ovarian Cancer, sponsored by Innovation Pharmaceuticals.

NCT03042702 is a Phase 2 study of Ovarian Cancer that has completed, run by Innovation Pharmaceuticals. The registered enrollment target is 2 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03042702, a Phase 2 study of Ovarian Cancer, has completed, sponsored by Innovation Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
2 participants
Enrollment target
2
Study locations

Study Summary

Cellceutix has developed Kevetrin (thioureidobutyronitrile), belonging to an anti-proliferative p53 activator pharmacological class, for the treatment of cancer. Nonclinical studies have demonstrated that Kevetrin induces apoptosis by activation of wild type p53 and induces apoptosis in mutant p53 cells by degradation of oncogenic mutant p53. In this Phase 2 study, two different short-term treatment regimens of Kevetrin will be evaluated for safety, tolerability, changes in biomarkers/objective tumor response, and to evaluate the pharmacokinetics of Kevetrin when administered to subjects with platinum-resistant/refractory ovarian cancer.

Primary Outcome

Reporting of Adverse Events, and severity of adverse events

Conditions Studied

Ovarian Cancer

Interventions

  • DRUG Kevetrin

Study Locations (2)

New Hampshire

  • Cancer Research - Lebanon

Texas

  • Cancer Research - Dallas

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2017-02-09
Est. Completion 2017-11-10
Phase Phase 2
Innovation Pharmaceuticals

4 total trials

What the finished NCT03042702 record still lists

NCT03042702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Kevetrin is the first listed.

NCT03042702 reports a single indexed study location in New Hampshire, Texas.

Frequently Asked Questions

What is clinical trial NCT03042702 about?

NCT03042702 is a clinical study titled "A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer". Cellceutix has developed Kevetrin (thioureidobutyronitrile), belonging to an anti-proliferative p53 activator pharmacological class, for the treatment of cancer. Nonclinical studies have demonstrated that Kevetrin induces apoptosis by activation of wild type p53 and induces apoptosis in mutant p53 c...

What is the current status of trial NCT03042702?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-02-09. Estimated completion is 2017-11-10.

What conditions does trial NCT03042702 study?

This clinical trial studies the following conditions: Ovarian Cancer.

What interventions are being tested in trial NCT03042702?

The interventions under investigation include: Kevetrin (DRUG).

Who is sponsoring clinical trial NCT03042702?

This trial is sponsored by Innovation Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03042702 being conducted?

This trial has 2 study locations across New Hampshire, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03042702's enrollment target sits among peer trials

2 322nd of 322 the lowest of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03042702, the US trial registry maintained by the National Library of Medicine. NCT03042702 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.